Miscellaneous
People with type 2 diabetes are at high risk of developing NASH, increasing their risk of poor outcomes. However, the only way to confirm a diagnosis of NASH is through liver biopsy, so how can we help identify people with NASH? This episode examines the currently available approaches to identifying NASH with Professor Arun Sanyal. For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. References: European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004. Epub 2016 Apr 7. PMID: 27062661. Chalasani N, et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357 Disclosures: Professor Arun Sanyal discloses: Consulting advisor: Conatus, GenFit, Gilead, malinckrodt, Pfizer, Salix, Boehringer Ingelhiem, Immuron, Intercept, Novartis, Bristol Myers, Merck, Hemoshear, Lilly, Novo Nordisk, Terns, Galectin, Sequana, Fractyl, Amra, Albireo, Sanofi, Jannsen, Takeda, Northsea, Owl, Poxel, 89 Bio, Siemens, Ngm Bio, Perspectum, Astra Zeneca, Biocellvia, Regeneron, Genentech, Roche, Madrigal, Inventiva, Albireo, Covance, Prosciento, Histoindex, Path Ai Research grants: Conatus, Gilead, Echosense-sandhill, Malinckrodt, Immuron, Boehringer Ingelhiem, Novartis, Bristol Myers, Merck, Lilly, Novo Nordisk, Fractyl, Owl, Second Genome, Siemens, Madrigal, Inventiva, Covance Royalties: Elsevier, Uptodate Stock: Sanyal Bio, Exhalenz, Akarna, Genfit, Hemoshear, Durect, Indalo, Tiziana, Rivus This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.